Targeting Cell-State Plasticity in Hepatocellular Carcinoma

Strategic Insights -

Researchers at Guangzhou Medical University have uncovered a crucial regulator of hierarchical cellular transitions in hepatocellular carcinoma (HCC), highlighting a potential target for cancer therapy. By analyzing public datasets and in vitro and in vivo models, the team identified the FOXM1/CEBPB axis as a key driver of developmental heterogeneity and therapeutic resistance in HCC. Their findings suggest that inhibiting FOXM1 can restore tumor developmental homogeneity, exposing tumor cells to immune surveillance.

Key Takeaways:

  • The FOXM1/CEBPB axis is a crucial regulator of hierarchical cellular transitions in HCC, driving developmental heterogeneity and therapeutic resistance.
  • Inhibiting FOXM1 restores tumor developmental homogeneity, exposing tumor cells to immune surveillance.
  • A GalNAc-conjugated, chemically modified siRNA lead compound targeting hepatic FOXM1 shows strong potency and tolerability in therapeutic mouse models.
  • RNAi-based therapies targeting hepatic FOXM1 demonstrate significant potential for further clinical testing.
  • The study reveals the strong efficacy of RNAi-based therapeutics directed at hepatic FOXM1 for cancer therapy.
  • Targeting the FOXM1/CEBPB axis has the potential to address tumor heterogeneity and therapeutic resistance in HCC.
  • The study highlights the importance of understanding cellular states and their transitions in the development of cancer therapies.
  • Xiao-Yu Zuo, Xiao-Feng Zhang, and colleagues demonstrate the restoration of developmental homogeneity and significant disruption of therapeutic resistance in preclinical models.

Statistics:

  • 77: The page number of the news report in Biotech Week.
  • Guangzhou Medical University: The institution where the researchers are based.
  • 1043 Nx Amsterdam, Netherlands: The address of Elsevier, the publisher of the Journal of Hepatology.
  • 2025: The year in which the research has been conducted and published.

Sources:

  • NewsRx. (2025, October 15). Researchers from Guangzhou Medical University Describe Findings in Cancer Gene Therapy (Targeting cell-state plasticity driven by FOXM1/CEBPB axis disrupts developmental heterogeneity and therapeutic resistance in hepatocellular carcinoma). Biotech Week, p 77.
  • Targeting cell-state plasticity driven by FOXM1/CEBPB axis disrupts developmental heterogeneity and therapeutic resistance in hepatocellular carcinoma. Journal of Hepatology, 2025.
  • Journal of Hepatology. Publisher: Elsevier. Address: Elsevier, Radarweg 29, 1043 Nx Amsterdam, Netherlands. Website: www.elsevier.com; www.journals.elsevier.com/journal-of-hepatology/
  • Xiao-Yu Zuo, Xiao-Feng Zhang, Yun Zhu, Jia-Xu Li, Jie-Shen Xian, Wen-Xin Zhang, Wei Cheng, Jun Yuan, Yuan-Feng Gong, Hui Tang, Xu-Qi Yang, Ying-Yue Su, Cheng-Yang Zhang, Shan-Shan Liu, Li Huang, Heng Wang, Mei-Mei Li, Shao-Yan Xi, Yun-Qiang Tang, and Lei Zho.